

Arvind Chhabra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3928772/publications.pdf>

Version: 2024-02-01

27
papers

585
citations

567281

15
h-index

610901

24
g-index

27
all docs

27
docs citations

27
times ranked

756
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Green Synthesis of Copper Oxide Nanoparticles using Cucumis Sativus (Cucumber) Extracts and their Bio-Physical and Biochemical Characterization for Cosmetic and Dermatologic Applications. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2021, 21, 726-733. | 1.2 | 5 |
| 2 | Medical tourism in the COVID-19 era: opportunities, challenges and the way ahead. <i>Worldwide Hospitality and Tourism Themes</i> , 2021, 13, 660-665. | 1.3 | 9 |
| 3 | Human Dendritic Cellâ€œDerived Induced Pluripotent Stem Cell Lines Are Not Immunogenic. <i>Journal of Immunology</i> , 2017, 198, 1875-1886. | 0.8 | 10 |
| 4 | Activation induced cell death (AICD) of human melanoma antigen-specific TCR engineered CD8 T cells involves JNK, Bim and p53. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 117-129. | 3.4 | 7 |
| 5 | Derivation of Human Induced Pluripotent Stem Cell (iPSC) Lines and Mechanism of Pluripotency: Historical Perspective and Recent Advances. <i>Stem Cell Reviews and Reports</i> , 2017, 13, 757-773. | 5.6 | 25 |
| 6 | Inherent Immunogenicity or Lack Thereof of Pluripotent Stem Cells: Implications for Cell Replacement Therapy. <i>Frontiers in Immunology</i> , 2017, 8, 993. | 4.8 | 11 |
| 7 | Suppression of inducible CD4 regulatory cells by MHC class I-restricted human tumor epitope specific TCR engineered multifunctional CD4 T cells. <i>Human Immunology</i> , 2016, 77, 905-911. | 2.4 | 1 |
| 8 | Functional antigen presenting cells generated from human dendritic cells (DC) derived induced pluripotent stem cell lines. , 2015, 3, . | | 0 |
| 9 | Analyses of T cell-mediated immune response to a human melanoma-associated antigen by the young and the elderly. <i>Human Immunology</i> , 2013, 74, 640-647. | 2.4 | 6 |
| 10 | Death Receptorâ€œIndependent Activation-Induced Cell Death in Human Melanoma Antigenâ€œSpecific MHC Class Iâ€œRestricted TCR-Engineered CD4 T Cells. <i>Journal of Immunology</i> , 2013, 191, 3471-3477. | 0.8 | 8 |
| 11 | Engineering Anti-Tumor T Cell Immunity. <i>Advancements in Genetic Engineering</i> , 2013, 02, . | 0.1 | 0 |
| 12 | TCR-Engineered, Customized, Antitumor T Cells for Cancer Immunotherapy: Advantages and Limitations. <i>Scientific World Journal, The</i> , 2011, 11, 121-129. | 2.1 | 14 |
| 13 | MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. <i>Clinical Immunology</i> , 2010, 136, 338-347. | 3.2 | 46 |
| 14 | Mitochondria-centric activation induced cell death of cytolytic T lymphocytes and its implications for cancer immunotherapy. <i>Vaccine</i> , 2010, 28, 4566-4572. | 3.8 | 24 |
| 15 | MHC Class I TCR Engineered Anti-Tumor CD4 T Cells: Implications For Cancer Immunotherapy. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2009, 9, 344-352. | 1.2 | 11 |
| 16 | Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma. <i>Clinics in Dermatology</i> , 2009, 27, 603-613. | 1.6 | 17 |
| 17 | Silencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-127â€œ35. <i>Clinical Immunology</i> , 2008, 126, 251-259. | 3.2 | 40 |
| 18 | Presence of Low Dose of Fludarabine in Cultures Blocks Regulatory T Cell Expansion and Maintains Tumor-Specific Cytotoxic T Lymphocyte Activity Generated with Peripheral Blood Lymphocytes. <i>Pathobiology</i> , 2008, 75, 200-208. | 3.8 | 24 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | CD4+CD25 ^{hi} T Cells Transduced to Express MHC Class I-Restricted Epitope-Specific TCR Synthesize Th1 Cytokines and Exhibit MHC Class I-Restricted Cytolytic Effector Function in a Human Melanoma Model. <i>Journal of Immunology</i> , 2008, 181, 1063-1070. | 0.8 | 43 |
| 20 | Inhibition of c-Jun N-terminal kinase rescues influenza epitope-specific human cytolytic T lymphocytes from activation-induced cell death. <i>Journal of Leukocyte Biology</i> , 2007, 81, 539-547. | 3.3 | 21 |
| 21 | Activation-induced cell death of human melanoma specific cytotoxic T lymphocytes is mediated by apoptosis-inducing factor. <i>European Journal of Immunology</i> , 2006, 36, 3167-3174. | 2.9 | 25 |
| 22 | Effect of CD4+CD25+ and CD4+CD25 ^{hi} T Regulatory Cells on the Generation of Cytolytic T Cell Response to a Self but Human Tumor-Associated Epitope In Vitro. <i>Journal of Immunology</i> , 2006, 176, 984-990. | 0.8 | 43 |
| 23 | <i>Vibrio cholerae</i> persistence in aquatic environments and colonization of intestinal cells: involvement of a common adhesion mechanism. <i>FEMS Microbiology Letters</i> , 2005, 244, 267-273. | 1.8 | 47 |
| 24 | Rescuing Melanoma Epitope-Specific Cytolytic T Lymphocytes from Activation-Induced Cell Death, by SP600125, an Inhibitor of JNK: Implications in Cancer Immunotherapy. <i>Journal of Immunology</i> , 2004, 173, 6017-6024. | 0.8 | 34 |
| 25 | Antigen presentation by MART ¹ adenovirus-transduced interleukin-10-polarized human monocyte-derived dendritic cells. <i>Immunology</i> , 2004, 113, 472-481. | 4.4 | 19 |
| 26 | Cross-presentation of a human tumor antigen delivered to dendritic cells by HSV VP22-mediated protein translocation. <i>European Journal of Immunology</i> , 2004, 34, 2824-2833. | 2.9 | 23 |
| 27 | Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. <i>Human Immunology</i> , 2004, 65, 794-802. | 2.4 | 72 |